title: Should intravenous immunoglobulin be used in infants with isoimmune haemolytic disease due to ABO incompatibility?
abstract: The use of intravenous immunoglobulin in isoimmune haemolytic disease due to ABO incompatibility is recommended by the American Academy of Pediatrics and the National Blood Authority, Australia. However, the evidence these recommendations are based on appears limited and, in some instances, outdated. In our article, we review the current available literature to help answer the question, 'In infants with isoimmune haemolytic disease due to ABO incompatibility [P], does use of intravenous immunoglobulin and intensive phototherapy [I] compared with intensive phototherapy alone [C] provide any clinically important benefits [O]?'
authors: Division of Neonatology, Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada; School of Paediatrics and Reproductive Health, University of Adelaide, South Australia, Australia.
authors: Amy K
authors: AK
authors: Keir
authors: Michael
authors: M
authors: Dunn
authors: Jeannie
authors: J
authors: Callum
mesh_terms: D000017:ABO Blood-Group System; D003131:Combined Modality Therapy; D004899:Erythroblastosis, Fetal / Q000628:therapy*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000627:therapeutic use*; D007231:Infant, Newborn; D010789:Phototherapy
chemical_list: D000017:ABO Blood-Group System; D016756:Immunoglobulins, Intravenous
keywords: anaemia; haemolytic; hyperbilirubinaemia; immunoglobulin; infant; newborn